EACS2023: 974 DOR-based therapy effectiveness as a switch regimen, real world study in Mexican population S. Triana-González , A. Cano-Díaz , J.A. Mata-Marín , J.E. Gaytán-Martínez Instituto Mexicano del Seguro Social, Ciudad de México, Mexico General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Antiretroviral treatment (ART) based on next-generation nonnucleoside inhibitors is usually indicated for switching therapy in virally suppressed people living with HIV (PLWH) due to simplification or toxicity management. Its efficacy and safety have been demonstrated in clinical trials, but information is insufficient under real-world conditions. The aim of this study was to assess indications for switching to a DOR-based therapy and to characterize effectiveness and effect on body weight of regimen at 24 weeks in virologically suppressed PLWH. Method: A single-center case series was conducted in Mexico. The included participants were PLWH virologically suppressed that were switched to a DOR-based regimen. Demographic, clinical, and laboratory data was collected from clinical records of routine consult visits, including baseline measures and at 24 weeks. Results: 19 male PLWH were included, the median age was 26 years (IQR 24-30). Median CD4+ cells count and HIV-1 viral load at diagnosis was 289 (IQR 192.7-448.5) and 27354 (IQR 10467-142555), respectively. Most frequent initial regimen was BIC/TAF/FTC 11/19 (57.9%) and most frequent comorbidities and comedications were neuropsychiatric and psychotropic drugs, with 12/19 (63.2%) and 11/19 (57.9%) cases. Median days for switch to DOR was 125 (IQR 35-317) and main reason for switch was to improve tolerability due to neuropsychiatric adverse effects (NPAE) in 11/19 (57.9%) subjects. Median BMI before and after switch was 26.3 (IQR 20.2-28.5) and 24.6 (IQR 21.3-28.8), respectively, with no statistical difference between measures (p=0.155) in exploratory analysis. No cases of virological failure were reported, with undetectable viral load at 24 weeks of switching in 19/19 (100%). Table 1. Demographic characteristics of patients on DOR-based regimen Age 26 (IQR 24-30) Sex Male Female 19 (100%) 0 Comorbidities Neuropsychiatric disorders Metabolic syndrome and other cardiovascular Dyslipidemia Gastrointestinal disorders 12 (63.2%) 5 (26.3%) 1 (5.3%) 1 (5.3%) Comedications Psychotropic drugs (SSRIs, antipsychotics, hypnotics, etc.) Drugs for metabolic disorders Drugs for cardiovascular disorders None 11 (57.9%) 4 (21.1%) 3 (15.8%) 1 (5.3%) Polypharmacy according to WHO definition, not including ART 3 (15.8%) Initial CD4+ cells count (cells/μl) 289 (IQR 192.7-448.5) Initial HIV-1 RNA viral load (copies/mL) 27354 (IQR 10467-142555) Initial antiretroviral regimen BIC/TAF/FTC DTG/ABC/3TC DRV/c+TDF/FTC EFV+TDF/FTC EVG/c/FTC/TAF 11 (57.9%) 4 (21.1%) 2 (10.5%) 1 (5.3%) 1 (5.3%) Indication for switch to DOR Neuropsychiatric disorders Metabolic syndrome and cardiovascular disease Gastrointestinal disorders 11 (57.9%) 5 (26.3%) 3 (15.8%) Median days for switch to DOR 125 (IQR 35-317) Table 2. Effectiveness of DOR-based regimen after 24 weeks Baseline 24 weeks P CD4+ cells count (cells/μl) before any treatment 289 (IQR 192.7-448.5) 717 (IQR 623.5-1055.5) <0.001 HIV-1 viral load (copies/mL) before any treatment 27354 (IQR 10467142555) <40 <0.001 HIV-1 viral load (copies/mL) at the moment of switch <40 (<40-<40) <40 (<40-<40) 1.0 Weight (kg) 72.7 (IQR 58.8-90.7) 82.2 (IQR 60.1-91.1) 0.245 BMI 26.3 (IQR 20.2-28.5) 24.6 (IQR 21.3-28.8) 0.155 Classification according to BMI Under weight Normal Overweight Grade 1 obesity Grade 2 obesity Grade 3 obesity 2 (10.5%) 6 (31.6%) 8 (42.1%) 2 (10.5%) 1 (5.3%) 0 2 (10.5%) 7 (36.8%) 5 (26.3%) 2 (10.5%) 1 (5.3%) 0 NA (a) The median CD4+ cell count and viral load presented are baseline determinations before the start of any treatment. (b) Missing data of two patients at 24 weeks. Conclusions: Data of this small study suggest that DOR-based ART is effective in maintaining viral suppression after 24 weeks, with no evidence of significative weight gain and NPAE. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 (a) (b) 184 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=